Sirtuin-targeting drugs: Mechanisms of action and potential therapeutic applications

被引:0
|
作者
Aljada, Ahmad [2 ]
Dong, Lynn [2 ]
Mousa, Shaker A. [1 ,3 ]
机构
[1] Albany Coll Pharm & Hlth Sci, Pharmaceut Res Inst, Rensselaer, NY 12144 USA
[2] Long Isl Univ, Dept Biomed Sci, Brookville, NY 11548 USA
[3] King Saud Univ, Riyadh 11451, Saudi Arabia
关键词
Cancer; longevity; neurodegenerative disease; protein deacetylase; resveratrol; sirtuin; small-molecule inhibitor; SMALL-MOLECULE ACTIVATORS; LIFE-SPAN EXTENSION; CALORIE RESTRICTION; SIR2; HOMOLOG; CELL-SURVIVAL; MITOCHONDRIAL-FUNCTION; GLUCOSE-HOMEOSTASIS; HISTONE DEACETYLASE; INSULIN-SECRETION; OXIDATIVE STRESS;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The sirtuins are NAD(+)-dependent histone/protein deacetylases that are similar to Saccharomyces cerevisiae silent information regulator 2 (Sir2). Sirtuins regulate various normal and abnormal cellular and metabolic processes, including tumorigenesis, neurodegeneration, and processes associated with type 2 diabetes and obesity. Several age-related diseases, such as Alzheimer's disease, and longevity have also been linked to the functions of sirtuins. A thorough understanding of the mechanisms of action of the sirtuins may therefore yield novel therapeutic strategies targeting these processes; several small-molecule and naturally occurring inhibitors and activators of these enzymes have been identified. This review describes the mechanisms regulating sirtuin activity, as well as how these modes of regulation may be exploited to manipulate activity in the context of various pathological states (ie, metabolic diseases, cancer and neurodegenerative diseases). The possible metabolic outcomes of the pharmacological manipulation of sirtuins are also discussed.
引用
收藏
页码:1158 / 1168
页数:11
相关论文
共 50 条
  • [1] Sirtuin 1 in Chronic Kidney Disease and Therapeutic Potential of Targeting Sirtuin 1
    Yan, Jiayi
    Wang, Jue
    He, John Cijiang
    Zhong, Yifei
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [2] Ursodeoxycholic acid in cholestasis: Potential mechanisms of action and therapeutic applications
    Beuers, U
    Boyer, JL
    Paumgartner, G
    HEPATOLOGY, 1998, 28 (06) : 1449 - 1453
  • [3] Calcimimetics, mechanisms of action and therapeutic applications
    Ureña, P
    Legoupil, N
    de Vernejoul, MC
    PRESSE MEDICALE, 2005, 34 (15): : 1095 - 1100
  • [4] PROLACTIN-LOWERING AND PROLACTIN-RELEASING DRUGS MECHANISMS OF ACTION AND THERAPEUTIC APPLICATIONS
    MULLER, EE
    LOCATELLI, V
    CELLA, S
    PENALVA, A
    NOVELLI, A
    COCCHI, D
    DRUGS, 1983, 25 (04) : 399 - 432
  • [5] THERAPEUTIC APPLICATIONS AND MECHANISMS OF ACTION OF MONOAMINE-OXIDASE INHIBITOR AND HETEROCYCLIC ANTIDEPRESSANT DRUGS
    GOODMAN, WK
    CHARNEY, DS
    JOURNAL OF CLINICAL PSYCHIATRY, 1985, 46 (10) : 6 - 22
  • [6] DNA topoisomerase targeting drugs: mechanisms of action and perspectives
    Malonne, H
    Atassi, G
    ANTI-CANCER DRUGS, 1997, 8 (09) : 811 - 822
  • [7] MECHANISMS OF ACTION OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND THERAPEUTIC CONSIDERATIONS
    ABRAMSON, SB
    BULLETIN OF THE HOSPITAL FOR JOINT DISEASES ORTHOPAEDIC INSTITUTE, 1990, 50 (02): : 107 - 115
  • [8] THERAPEUTIC APPLICATIONS AND MECHANISMS OF ACTION OF MONOAMINE-OXIDASE INHIBITOR AND HETEROCYCLIC ANTIDEPRESSANT DRUGS - DISCUSSION
    SALZMAN
    CHARNEY
    OSTROW
    ADDARIO
    JOURNAL OF CLINICAL PSYCHIATRY, 1985, 46 (10) : 23 - 24
  • [9] The therapeutic potential of drugs targeting the arginase pathway in asthma
    Ricciardolo, FLM
    Zaagsma, J
    Meurs, H
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (10) : 1221 - 1231
  • [10] Therapeutic Potential of Drugs Targeting Pathophysiology of Intracerebral Hemorrhage: From Animal Models to Clinical Applications
    Liao, Kuo-Hsing
    Sung, Chih-Wei
    Huang, Ya-Ni
    Li, Wei-Jiun
    Yu, Po-Chuan
    Wang, Jia-Yi
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (15) : 2212 - 2225